Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

JHOP - April 2022 Vol 12, No 2

Protecting Patients with Cancer During the COVID-19 Pandemic

Robert Mancini, PharmD, BCOP, FHOPA, and Timothy G. Tyler, PharmD, FCSHP, FHOPA

Case Reports

Arsenic Trioxide–Induced QTc Interval Prolongation and the Potential Benefit of Beta-Blockers in Patients with Acute Promyelocytic Leukemia: Case Series

Nada Alsuhebany, BSPharmD, PharmD, BCOP; Marti Larriva, PharmD, BCPS, BCOP; Ali McBride, PharmD, MS, BCPS, BCOP, FASHP; Krisstina Gowin, DO

Original Article

Impact of Letermovir for Cytomegalovirus Prophylaxis in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation

Brianna Archambeau, PharmD, BCOP; Ashley M. Leece, PharmD, BCOP, BCPS; Dhaval Patel, PharmD, BCOP; Chin Y. Liu, MS, PharmD, BCOP

Hepatitis B Virus Infection Monitoring in Patients with Lymphoma Receiving Anti-CD20 Monoclonal Antibodies

Christopher Sinoimeri, PharmD; Bryan Do, PharmD, BCOP; Sheree Chen, PharmD, BCOP

Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent

Donyika Joseph, PharmD, BCOP; Farnaz Foolad, PharmD, BCPS; Neelam K. Patel, PharmD, BCOP; Meghan Karuturi, MD, MSc; Jaime Kaushik, PharmD, BCOP

Review Article

Comparison of Second-Generation Antiandrogens for the Treatment of Prostate Cancer

Seon Jo Park, PharmD, BCOP; Benjamin Yoder, PharmD; Tammy Li, PharmD

FDA Oncology Update

Pluvicto FDA Approved for PSMA-Positive Metastatic Prostate Cancer

Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC

Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation

Keytruda Monotherapy FDA Approved for Endometrial Carcinoma with a Biomarker

Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma

Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma

ASCO Highlights

Neoadjuvant Enfortumab Vedotin Therapy Promising in Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin

Sacituzumab plus Pembrolizumab Shows Promising Antitumor Activity in Metastatic Urothelial Cancer

Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

Continuous Treatment with Enzalutamide and Docetaxel Reduces the Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer

From the Literature

First-Line Nivolumab Combination Therapy Improves Survival in Patients with Advanced Esophageal Squamous-Cell Carcinoma: CheckMate-648

Second-Line Axicabtagene Ciloleucel Therapy Improves Outcomes in Patients with Large B-Cell Lymphoma: ZUMA-7

Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522